Literature DB >> 18243334

The functionality and economic costs of outpatients with schizophrenia in Taiwan.

I Hui Lee1, Po See Chen, Yen Kuang Yang, Yi Cheng Liao, Yih Dar Lee, Tzung Lieh Yeh, Ling Ling Yeh, Shu Hui Cheng, Ching Lin Chu.   

Abstract

The aims of this study were to investigate the economic costs of outpatients with schizophrenia in Taiwan, and to survey factors that influence the costs. The direct costs were defined as the costs associated with psychiatric services and other medical treatment. The indirect costs were estimated using the Human Capital Method. Patients' characteristics, including sex, age, duration of education, duration of illness, frequency of hospitalization, type of antipsychotic medication, severity of extrapyramidal side effects caused by antipsychotic medication, and global functions, were used to estimate the costs. The average annual total cost was approximately US$16,576 per patient. The direct and indirect costs were 13% and 87% of the total costs, respectively. Among the direct costs, folk therapy ranked third, just behind prescription drugs and acute ward hospitalization. The productivity loss of both the patients and their caregivers was the major component of the indirect costs. The patient's age and global functions had a significantly negative relationship with the direct costs. The severity of extrapyramidal side effects, type of antipsychotic medication, and the patient's illness duration correlated positively with the indirect costs, while the patient's global function correlated negatively with the indirect costs. Overall, the indirect costs of treating schizophrenia were higher than the direct costs. Improving patients' functionality and decreasing caregivers' burden are essential to reducing costs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243334     DOI: 10.1016/j.psychres.2006.10.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  12 in total

1.  Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.

Authors:  Pudtan Phanthunane; Theo Vos; Harvey Whiteford; Melanie Bertram
Journal:  Cost Eff Resour Alloc       Date:  2011-05-13

2.  Out-of-pocket health expenditures in patients with bipolar disorder, anxiety, schizophrenia and other psychotic disorders: findings from a study in a psychiatry outpatient clinic in Turkey.

Authors:  Duygu Islek; Bulent Kilic; Berna Binnur Akdede
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-11-28       Impact factor: 4.328

3.  Transdiagnostic comparisons of intellectual abilities and work outcome in patients with mental disorders: multicentre study.

Authors:  Chika Sumiyoshi; Kazutaka Ohi; Haruo Fujino; Hidenaga Yamamori; Michiko Fujimoto; Yuka Yasuda; Yota Uno; Junichi Takahashi; Kentaro Morita; Asuka Katsuki; Maeri Yamamoto; Yuko Okahisa; Ayumi Sata; Eiichi Katsumoto; Michihiko Koeda; Yoji Hirano; Masahito Nakataki; Junya Matsumoto; Kenichiro Miura; Naoki Hashimoto; Manabu Makinodan; Tsutomu Takahashi; Kiyotaka Nemoto; Toshifumi Kishimoto; Michio Suzuki; Tomiki Sumiyoshi; Ryota Hashimoto
Journal:  BJPsych Open       Date:  2022-06-03

4.  The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Authors:  William Montgomery; Li Liu; Michael D Stensland; Hai Bo Xue; Tamas Treuer; Haya Ascher-Svanum
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-14

5.  An investigation of economic costs of schizophrenia in two areas of China.

Authors:  Jinguo Zhai; Xiaofeng Guo; Min Chen; Jingping Zhao; Zhonghua Su
Journal:  Int J Ment Health Syst       Date:  2013-11-15

Review 6.  Global economic burden of schizophrenia: a systematic review.

Authors:  Huey Yi Chong; Siew Li Teoh; David Bin-Chia Wu; Surachai Kotirum; Chiun-Fang Chiou; Nathorn Chaiyakunapruk
Journal:  Neuropsychiatr Dis Treat       Date:  2016-02-16       Impact factor: 2.570

Review 7.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

8.  Cost burden of post stroke condition in Nigeria: a pilot study.

Authors:  Bridget N Birabi; Kayode Israel Oke; Paul O Dienye; Udoka Chris Okafor
Journal:  Glob J Health Sci       Date:  2012-08-15

9.  Factors predicting work outcome in Japanese patients with schizophrenia: role of multiple functioning levels.

Authors:  Chika Sumiyoshi; Philip D Harvey; Manabu Takaki; Yuko Okahisa; Taku Sato; Ichiro Sora; Keith H Nuechterlein; Kenneth L Subotnik; Tomiki Sumiyoshi
Journal:  Schizophr Res Cogn       Date:  2015-09-09

10.  Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.

Authors:  Pedro Such; José Manuel Olivares; Lizbeth Arias; Mette Troels Berg; Jessica Madera
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.